Search

Your search keyword '"Topp, M"' showing total 331 results

Search Constraints

Start Over You searched for: Author "Topp, M" Remove constraint Author: "Topp, M"
331 results on '"Topp, M"'

Search Results

1. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

2. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

3. NLO Monte Carlo predictions for heavy-quark production at the LHC: pp collisions in ALICE

4. Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.

5. 3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplant

6. Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study

8. CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie

10. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

11. P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3

12. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

13. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

16. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

19. CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS

20. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS

22. Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial

23. Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group

24. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer

35. Blinatumomab (Anti-CD19 BiTE®) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study: V341

36. Treatment with 2 cycles of BEACOPPesc followed by 2 cycles of ABVD and IF-RT is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 trial: V336

39. Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study

45. PS1240 EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I)

46. S825 EVALUATION OF AMG 420, AN ANTI‐BCMA BISPECIFIC T‐CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST‐IN‐HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

49. The Sensitivity of Rapid Tests for SARS-CoV-2 Antigen: Association With Clinical Manifestations, Viral Load, and Sublines: Association with clinical manifestations, viral load, and sublines.

50. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Catalog

Books, media, physical & digital resources